Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis

• Published in: The New England journal of medicine Vol. 340; no. 1; pp. 23 - 30
• Main Authors: Ramsey, Bonnie W, Pepe, Margaret S, Quan, Joanne M, Otto, Kelly L, Montgomery, A. Bruce, Williams-Warren, Judy, Vasiljev-K, Michael, Borowitz, Drucy, Bowman, C. Michael, Marshall, Susan, Marshall, Bruce C, Smith, Arnold L
• Format: Journal Article
• Language: English
• Published: Boston, MA Massachusetts Medical Society 07.01.1999
• Subjects: Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Biological and medical sciences; Cystic fibrosis; Infections; Medical sciences; Pharmacology. Drug treatments; Pseudomonadales; Multicenter study; Nebulization; Randomization; Lung function; Intermittent; Bacteria; Pseudomonadaceae; Pseudomonas aeruginosa; Child; Pancreatic disease; Human; Respiratory disease; Metabolic diseases; Cystic fibrosis; Genetic disease; Inhalation; Infection; Antibiotic; Treatment; Aminoglycoside; Young adult; Bacteriosis; Double blind study; Digestive diseases; Application method; Tobramycin; Antibacterial agent
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJM199901073400104

Periodic exacerbations of Pseudomonas aeruginosa endobronchial infection in patients with cystic fibrosis have traditionally been treated with parenteral antipseudomonal antibiotics for 7 to 21 days. 1 Despite frequent intravenous therapy, patients continue to have a decline in pulmonary function of approximately 2 percent per year, and eventually 90 percent of such patients die of lung disease. 2 , 3 Thus, long-term antibacterial therapy may help maintain pulmonary function. Other investigators have used inhalation to deliver antibiotics directly to the site of infection. 4 – 7 However, these studies have been limited by small numbers of subjects, short duration, uncertain delivery of antibiotics to the airways, . . .